Crestor gets FDA nod for atherosclerosis

LONDON Astra Zeneca’s Crestor, used to break down artery-blocking fat deposits that cause strokes and heart attacks, is the first cholesterol medication to win Food and Drug Administration clearance to be marketed as effective against atherosclerosis, London-based AstraZeneca has said.

Atherosclerosis is a progressive disease and the main cause of heart disease, the world’s biggest killer. The medicine was approved as a therapy to slow the progression of the disease, FDA spokesman Christopher Kelly told Bloomberg News.

AstraZeneca, which bought the rights to Crestor from Japan’s Shionogi & Co., received $691 million from the pill in the third quarter, up 29 percent from a year earlier. The company expects sales to increase following the FDA approval for the new use.

AstraZeneca is the U.K.’s second largest drugmaker after GlaxoSmithKline Plc.

Login or Register to post a comment.